Sickle Cell Disease (Anemia)
Child and Young Development (PSC 1246A)
Sickle Cell Disease, commonly referred to as Sickle Cellular Anemia, is a blood disease which red blood form an abnormal sickle or new-moon shape. Blood carry fresh air to the body and are normally shaped like a disc. This kind of disease can be genetically handed down from the two parents. In case you inherit the sickle cell gene via only one parent or guardian, you will have sickle cell attribute. People with sickle cell feature do not have the symptoms of sickle cell low blood count. Sickle cellular disease is much more common in people of Photography equipment and Mediterranean descent. It is also seen in people from Southern and Central America, the Caribbean, and the Middle East. Sickle cellular anemia is caused by an abnormal form of hemoglobin[-> 0] called hemoglobin S. Just one cell triggers this disease. Hemoglobin can be described as protein inside red blood cells that carries fresh air. The fragile, sickle-shaped cells deliver less o2 to the human body's tissues, and in addition get caught more easily in small blood vessels, as well as enter pieces that may interrupt healthier blood flow. These types of problems cure the amount of oxygen flowing to body tissues a lot more, sometimes causing a crisis. A crisis is a unpleasant episode, sometimes lasting via hours to days, of pain in the back, lengthy bones and the chest. These episodes often start following four months of age, generally lasting until death. In young children these episodes consist of, attacks of abdominal pain, fatigue, jaundice, rapid heart rate, shortness of breath and paleness. As a person grows older together with the disease, little blood vessels can become blocked by abnormal cells causing painful and prolonged erection typically referred to as priapism, poor eyesight or perhaps blindness, problems thinking or confusion due to small cerebral vascular accidents, and ulcer on the calves of adults and children. Usually a person together with the disease will certainly sooner or later lose their spleen and have other symptoms and...
References: 1 . Rees POWER, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010; 376(9757): 2018-2031.
2 . Shelter MT, Piomelli S, Granger S, ain al. Cerebrovascular accident prevention trial in sickle cell anemia (STOP): extended follow-up and final results. Blood vessels. 2006; 108: 847-852.
several. Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi C, et al. National Institutes of Well being consensus advancement conference declaration: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 08; 148: 932-938.
4. Geller AK, O 'Connor MK. The sickle cell turmoil: a situation in treatment. Mayo Clin Proc. 2008; 83: 320-323.
Review Date: 2/7/2012.
Reviewed by: Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. As well reviewed by David Zieve, MD, MHA, Medical Movie director, A. G. A. Meters. Health Solutions, Ebix, Incorporation